Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

被引：0
|
作者：
Lingyun Wu
Xiao Li
Jiying Su
Qi He
Xi Zhang
Chunkang Chang
Quan Pu
机构：
[1] The Sixth Hospital Affiliated to Shanghai Jiaotong University,Department of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2011年 / 137卷
关键词：
Myelodysplastic syndromes; Acute myeloid leukemia; Cytarabine; Homoharringtonine; Granulocyte colony-stimulating factor (G-CSF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1563 / 1569
页数：6
相关论文
共 50 条
  • [31] Consolidation of complete remission with high-dose chemotherapy and autologous stem cell rescue in AML and high-risk MDS elderly patients: feasibility and preliminary results
    Bernardi, M
    Tassara, M
    Ciceri, F
    Peccatori, J
    Lunghi, F
    Pescarollo, A
    Camba, L
    Calbi, V
    Bregni, M
    BONE MARROW TRANSPLANTATION, 2005, 35 : S223 - S223
  • [32] Upfront randomized TAD-HAM vs HAM-HAM induction, G-CSF priming vs no G-CSF, and prolonged maintenance vs autologous transplantation in de novo AML, secondary AML and high-risk MDS and their subgroups according to cytogenetics and LDH:: Interim analysis.
    Buechner, T
    Hiddemann, W
    Berdel, WE
    Wörmann, B
    Haferlach, T
    Schoch, C
    Ludwig, WD
    Maschmeyer, G
    Kienast, J
    Serve, H
    Staib, P
    Reichle, A
    Balleisen, L
    Aul, C
    Giagounidis, A
    Eimermacher, H
    Rasche, H
    Grüneisen, A
    Hartlapp, J
    Trümper, L
    Lengfelder, E
    Pielken, HJ
    Weh, HJ
    Notter, M
    Trenn, G
    Heinecke, MC
    Sauerland, A
    BLOOD, 2002, 100 (11) : 345A - 345A
  • [33] A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities
    Butera, J.
    Winer, E.
    Wang, C.
    Castillo, J. J.
    Thomas, A. G.
    Safran, H.
    Mega, A. E.
    Colvin, G. A.
    Rathore, B.
    Quesenberry, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome
    Wu, Lingyun
    Li, Xiao
    Su, Jiying
    Chang, Chunkang
    He, Qi
    Zhang, Xi
    Xu, Li
    Song, Luxi
    Pu, Quan
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1461 - 1467
  • [35] WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED BY ALLO-HSCT
    Cao, J.
    Shi, X.
    Ge, L.
    Sun, A.
    Zhu, X.
    Qiu, H.
    Jin, Z.
    Miao, M.
    Fu, C.
    Ma, X.
    Chen, F.
    Xue, S.
    Han, Y.
    Xue, M.
    Mao, X.
    Wu, D.
    Tang, X.
    HAEMATOLOGICA, 2016, 101 : 286 - 286
  • [36] Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS
    Bernasconi, C
    Alessandrino, EP
    Bernasconi, P
    Bonfichi, M
    Lazzarino, M
    Canevari, A
    Castelli, G
    Brusamolino, E
    Pagnucco, G
    Castagnola, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) : 678 - 683
  • [37] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Aclarubicin, Low-Dose Cytarabine Combined With G-CSF (CAG) Regimen For Patients Previously Treated Or Ineligible For Intensive Chemotherapy With Acute Myeloid Leukemia and Myelodysplastic Syndrom: A Single Center Experience
    Minauchi, Koichiro
    Obara, Masato
    Ara, Takahide
    Shima, Kanako
    Yasumoto, Atsushi
    Nakata, Masanobu
    Ota, Shuichi
    Imai, Kiyotoshi
    Hirano, Teiichi
    Kiyama, Yoshio
    Ogasawara, Masahiro
    Kobayashi, Naoki
    Imamura, Masahiro
    BLOOD, 2013, 122 (21)
  • [39] Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia
    Huang, Jiayu
    Hong, Ming
    Zhu, Yu
    Zhao, Huihui
    Zhang, Xiaoyan
    Wu, Yujie
    Lian, Yun
    Zhao, Xiaoli
    Li, Jianyong
    Qian, Sixuan
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2570 - 2579
  • [40] Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years
    Wang, Fang
    Xu, Wenyan
    Liu, Li
    Ren, Xiuhong
    Liu, Pingping
    Zheng, Li
    Zhang, Hao
    Zhang, Songsong
    Xu, Yaru
    Guo, Zhenxing
    HEMATOLOGY, 2021, 26 (01) : 1040 - 1045
12345